Holen Sie sich die Stockscreener-App
5.33
1.33%
0.07
Handel nachbörslich:
5.43
0.10
+1.88%
Schlusskurs vom Vortag:
$5.26
Offen:
$5.37
24-Stunden-Volumen:
1.29M
Relative Volume:
0.82
Marktkapitalisierung:
$1.09B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-129.48M
KGV:
-9.5451
EPS:
-0.5584
Netto-Cashflow:
$-106.97M
1W Leistung:
+5.34%
1M Leistung:
+5.96%
6M Leistung:
-19.36%
1J Leistung:
+141.18%
1-Tages-Spanne:
$5.315
$5.525
1-Wochen-Bereich:
$4.73
$5.525
52-Wochen-Spanne:
$1.98
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.33 | 1.08B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com UK
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com - Investing.com South Africa
Savara Expands Share Capital and Updates Executive Leadership - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle - Pluang
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role By Investing.com - Investing.com Australia
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role - Investing.com Australia
Savara Announces Chief Financial And Administrative Officer Transition - TradingView
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO - Stock Titan
Savara Announces Chief Financial and Administrative Officer Transition - The Joplin Globe
Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 - marketscreener.com
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns - Yahoo Finance
SVRA News | SAVARA INC (NASDAQ:SVRA) - ChartMill
SVRA: All proposals, including director elections and plan amendments, were approved - TradingView
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease - MyChesCo
SVRA Q1 2026 Earnings: Narrowing Loss and Operational ProgressRevenue Estimate Trend - newsline.com
Savara Reports Long-Term Phase 3 Data Supporting Molgramostim Durability - MyChesCo
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial - MyChesCo
Savara Inc. (SVRA) Q1 2026 Earnings: EPS Miss Reflects Investment Phase as Pipeline AdvancesGeographic Revenue Trends - newsline.com
SVRA Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressAnalyst Coverage Count - The Legal Advocate
SVRA Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEarnings Revision Downgrade - newsline.com
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Savara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Finance
Savara Inc stock (US80633A1025): Jefferies conference appearance keeps rare-disease biotech in focus - AD HOC NEWS
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Pipeline DevelopmentAnalyst Coverage Count - thelegaladvocate.com
Rare lung disease biotech Savara heads to Jefferies investor conference - Stock Titan
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The Joplin Globe
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA) - Seeking Alpha
Savara Advances MOLBREEVI Toward FDA Decision as Loss Widens - MyChesCo
SVRA Q1 2026 Earnings: Wider Loss Amid Continued Pipeline DevelopmentEarnings Momentum Score - newsline.com
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Development - thelegaladvocate.com
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara (SVRA) - simplywall.st
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates Pipeline CostsGuidance Update - thelegaladvocate.com
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Savara Inc. (SVRA) Faces Modest Pullback as Shares Test Support Levels Near $5.00Sector Sentiment - The Legal Advocate
Savara Inc. (SVRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Savara Inc. (SVRA) Reports Q1 Financial Results - Insider Monkey
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus - AD HOC NEWS
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - BioSpace
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Savara presents biomarker data from molgramostim trial at ATS By Investing.com - Investing.com South Africa
Savara presents biomarker data from molgramostim trial at ATS - Investing.com
Savara (SVRA) Reports New Clinical Findings at ATS 2026 Conferen - GuruFocus
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):